drugset / Trial / NCT00004162
Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma
Phase 1
Completed
48 enrolled
University of Alabama at Birmingham
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of liposomal doxorubicin plus combination chemotherapy in treating patients who have AIDS-associated non-Hodgkin's lymphoma.
Timeline
- Start
- 1997-06
- Primary completion
- 2001-01
- Completion
- 2001-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | — | Intravenous |
| Background | Methotrexate | Small molecule | — | Intrathecal |
| Background | Vincristine | Small molecule | — | Intravenous |
| Background | sargramostim | Protein / enzyme biologic | — | Subcutaneous |